JP2018500322A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500322A5
JP2018500322A5 JP2017532039A JP2017532039A JP2018500322A5 JP 2018500322 A5 JP2018500322 A5 JP 2018500322A5 JP 2017532039 A JP2017532039 A JP 2017532039A JP 2017532039 A JP2017532039 A JP 2017532039A JP 2018500322 A5 JP2018500322 A5 JP 2018500322A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
composition according
years
vzv
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500322A (ja
Filing date
Publication date
Priority claimed from GB201503266A external-priority patent/GB201503266D0/en
Priority claimed from GBGB1518917.8A external-priority patent/GB201518917D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/079967 external-priority patent/WO2016096968A1/en
Publication of JP2018500322A publication Critical patent/JP2018500322A/ja
Publication of JP2018500322A5 publication Critical patent/JP2018500322A5/ja
Pending legal-status Critical Current

Links

JP2017532039A 2014-12-18 2015-12-16 ワクチン接種 Pending JP2018500322A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201422686 2014-12-18
GB1422686.4 2014-12-18
GB201503266A GB201503266D0 (en) 2015-02-26 2015-02-26 Vaccination
GB1503266.7 2015-02-26
GB1518917.8 2015-10-26
GBGB1518917.8A GB201518917D0 (en) 2015-10-26 2015-10-26 Vaccination
PCT/EP2015/079967 WO2016096968A1 (en) 2014-12-18 2015-12-16 Vaccination

Publications (2)

Publication Number Publication Date
JP2018500322A JP2018500322A (ja) 2018-01-11
JP2018500322A5 true JP2018500322A5 (enExample) 2018-12-27

Family

ID=54937057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532039A Pending JP2018500322A (ja) 2014-12-18 2015-12-16 ワクチン接種

Country Status (8)

Country Link
US (1) US20180008700A1 (enExample)
EP (1) EP3233118A1 (enExample)
JP (1) JP2018500322A (enExample)
CN (1) CN107106675A (enExample)
BR (1) BR112017012647A2 (enExample)
CA (1) CA2970840A1 (enExample)
MX (1) MX2017008055A (enExample)
WO (1) WO2016096968A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201803360UA (en) * 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
CN110582282A (zh) 2017-04-25 2019-12-17 佐剂技术公司 三萜皂苷类似物
US20210187098A1 (en) * 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
CN112189017B (zh) * 2018-05-23 2024-12-27 财团法人牧岩生命科学研究所 水痘带状疱疹病毒的抗原变体及其用途
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
AU2020379738A1 (en) * 2019-11-05 2022-04-14 Adjuvance Technologies, Inc. Varicella zoster
US12569553B2 (en) 2020-03-09 2026-03-10 Dynavax Technologies Corporation Shingles vaccines comprising a TLR9 agonist
US20250325656A1 (en) * 2022-05-20 2025-10-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物

Similar Documents

Publication Publication Date Title
US20230116042A1 (en) Adjuvant formulations comprising tlr4 agonists and methods of using the same
EP2664332B1 (en) Vaccine composition containing synthetic adjuvant
US11951161B2 (en) Methods for inducing an immune response
Kamphuis et al. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats
CN1391483A (zh) 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用
HUP0203817A2 (hu) Polioxietilén-alkil-étert vagy -észtert és legalább egy nemionos felületaktív anyagot tartalmazó adjuváns
BRPI0716959A2 (pt) Composição de vacina contendo adjuvante sintético
JP2018500322A (ja) ワクチン接種
JP2017511327A5 (enExample)
CN110621339A (zh) 疫苗接种
JP2017511324A5 (enExample)
CA3157372A1 (en) Varicella zoster
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
WO2012042003A1 (en) Improved vaccine compositions
EP3119428B1 (en) Toll-like receptor 2 agonists and vaccines and uses thereof
AR103030A1 (es) Composición inmunógena
Lee EFFECTS OF VACCINE PLATFORMS AND ADJUVANTS ON PROTECTIVE EFFICACY AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS
TH94291A (th) สารผสมวัคซีนที่ได้เสริมฤทธิ์โดยที่สารเสริม คือ สูตรผสมไลโปโซมที่ประกอบรวมด้วยซาโปนิน และไลโปพอลิแซ็กคาไรด์
HK1240138A1 (en) Vaccine composition containing synthetic adjuvant